Literature DB >> 28627963

The natural history of recovery of elbow flexion after obstetric brachial plexus injury managed without nerve repair.

T E J Hems1, T Savaridas1, D A Sherlock1.   

Abstract

In this study, we report the outcome for spontaneous recovery of elbow flexion in obstetric brachial plexus injury managed without nerve reconstruction. Excluding those with transient paralysis, our records revealed 152 children with obstetric brachial plexus injury born before our unit routinely offered brachial plexus reconstruction. Five had had nerve repairs. Of the remainder, only one patient had insufficient flexion to reach their mouth. Elbow flexion started to recover clinically at a mean age of 4 months for Narakas Group 1, 6 months for Group 2, 8 months for Group 3 and 12 months for Group 4. The mean active range of elbow flexion, in 44 cases, was 138°. The mean isometric elbow flexion strength, in 39 patients, was 63% (range 23%-100%) of the normal side. It appears to be rare for elbow flexion not to recover spontaneously, although recovery occurs later in more severe injuries. It is doubtful if nerve reconstruction can improve elbow flexion above the likely spontaneous recovery in babies with obstetric brachial plexus injuries. LEVEL OF EVIDENCE: II.

Entities:  

Keywords:  Brachial plexus; elbow flexion; natural history; nerve repair; obstetric injury

Mesh:

Year:  2017        PMID: 28627963     DOI: 10.1177/1753193417712924

Source DB:  PubMed          Journal:  J Hand Surg Eur Vol        ISSN: 0266-7681


  2 in total

Review 1.  Evidence that nerve surgery improves functional outcome for obstetric brachial plexus injury.

Authors:  Willem Pondaag; Martijn J A Malessy
Journal:  J Hand Surg Eur Vol       Date:  2020-06-26

Review 2.  The impact of imposed delay in elective pediatric neurosurgery: an informed hierarchy of need in the time of mass casualty crisis.

Authors:  Ranbir Ahluwalia; Brandon G Rocque; Chevis N Shannon; Jeffrey P Blount
Journal:  Childs Nerv Syst       Date:  2020-05-20       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.